Scholarlink

Background <p><i>Mycobacterium abscessus</i> (MAB), a rapidly growing non-tuberculous mycobacterium, presents severe therapeutic challenges due to its intrinsic and acquired multidrug resistance. Notably, MAB exhibits phenotypic heterogeneity, with smooth (S) and rough (R) morphotypes displaying distinct drug susceptibility phenotypes.</p> Results <p>We systematically examined the phenotypic diversity and drug susceptibility profiles of 100 clinical MAB isolates, including 79 R-type, 13&#xa0;S-type, and 8 mixed (M) morphotypes. The three morphotypes (R, S, M) exhibited distinct drug resistance profiles. Both R-type and S-type strains showed broad-spectrum resistance to fluoroquinolones, tetracycline derivatives, and carbapenems. In contrast, S-type strains remained fully susceptible to clofazimine (CFZ), linezolid (LNZ), and trimethoprim-sulfamethoxazole (TMS). Notably, significant differences in resistance to capreomycin (CAP) and clofazimine (CFZ) were observed among the three morphotypes. Genotypic analysis revealed a homogeneous distribution of key resistance genes (<i>erm</i>(41), <i>rrl</i>, <i>rrs</i>) across morphotypes.</p> Conclusions <p>Our findings highlight the relationship between MAB morphotypes and antibiotic resistance is complex and drug specific. It is necessary to integrate morphotype with genotypic profiling and phenotypic characterization to better understand the complex resistance landscape of MAB and to guide more effective therapeutic strategy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative analysis of drug susceptibility among different Mycobacterium abscessus morphotypes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月26日

查看全文
  • Kai Cheng,
  • Jiaying Guo,
  • Yuanyuan Shang,
  • Weicong Ren,
  • Weijie Zhao,
  • Shanshan Li

摘要

Background

Mycobacterium abscessus (MAB), a rapidly growing non-tuberculous mycobacterium, presents severe therapeutic challenges due to its intrinsic and acquired multidrug resistance. Notably, MAB exhibits phenotypic heterogeneity, with smooth (S) and rough (R) morphotypes displaying distinct drug susceptibility phenotypes.

Results

We systematically examined the phenotypic diversity and drug susceptibility profiles of 100 clinical MAB isolates, including 79 R-type, 13 S-type, and 8 mixed (M) morphotypes. The three morphotypes (R, S, M) exhibited distinct drug resistance profiles. Both R-type and S-type strains showed broad-spectrum resistance to fluoroquinolones, tetracycline derivatives, and carbapenems. In contrast, S-type strains remained fully susceptible to clofazimine (CFZ), linezolid (LNZ), and trimethoprim-sulfamethoxazole (TMS). Notably, significant differences in resistance to capreomycin (CAP) and clofazimine (CFZ) were observed among the three morphotypes. Genotypic analysis revealed a homogeneous distribution of key resistance genes (erm(41), rrl, rrs) across morphotypes.

Conclusions

Our findings highlight the relationship between MAB morphotypes and antibiotic resistance is complex and drug specific. It is necessary to integrate morphotype with genotypic profiling and phenotypic characterization to better understand the complex resistance landscape of MAB and to guide more effective therapeutic strategy.